Inhalable tRNA therapy restores protein function in cystic fibrosis mice

Key points

• A study in Science details how modified tRNA delivered via inhalation restored CFTR protein function in mice with cystic fibrosis.
• The therapy remained in lung epithelial cells for up to 40 days, offering greater persistence than typical mRNA treatments.
• In patient-derived organoids, the modified tRNA combined with Vertex’s Trikafta to restore protein function where Trikafta alone failed.
• Lead author Bowen Li plans to initiate clinical trials within two to three years, targeting diseases like Duchenne muscular dystrophy and Rett syndrome.
• The method uses suppressor tRNAs to read through premature stop codons without altering the genome, avoiding risks associated with gene editing.

Background

This development follows recent successes in mRNA technology, including the FDA approval of an mRNA flu vaccine in August 2026 and positive phase 3 results for Moderna and Merck’s personalized cancer vaccine. While mRNA has dominated the RNA therapeutic landscape due to COVID-19 vaccines, its short half-life and potential for immune activation have prompted research into alternative RNA modalities like tRNA for chronic genetic conditions.

How outlets are covering it

Fierce Biotech emphasizes the practical advantages of tRNA over mRNA, noting its longer persistence in tissues and ability to handle large protein deficiencies without size constraints. Hindustan Times frames the discovery as a 'biological bypass' that corrects errors during protein production rather than editing DNA, highlighting its potential as a reversible and safe platform for multiple diseases. Both outlets agree on the significance of the Science publication but differ in focus: Fierce Biotech details the specific synergy with Trikafta and clinical timelines, while Hindustan Times stresses the broader applicability of the platform across various genetic disorders.

Why it matters

This research provides a new therapeutic avenue for the approximately 11% of human genetic disorders caused by nonsense mutations, which are often unresponsive to current treatments. By restoring endogenous protein expression without permanent genomic changes, tRNA therapy could offer safer, long-term solutions for patients with cystic fibrosis, muscular dystrophy, and other conditions lacking effective therapies.

What to watch

Bowen Li’s team aims to move the inhalable tRNA therapy into human clinical trials within the next two to three years. Researchers are currently testing the platform in other disease contexts, including Duchenne muscular dystrophy and Rett syndrome, while optimizing delivery systems for organs beyond the lungs, such as the liver and central nervous system.